Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“Congrats to Deepak for presenting our latest analysis of the evolving phase 1 oncology landscape!
From the rise of KRAS-targeted agents to the ADC boom (mainly TOP1 payloads), early-phase trials are shifting fast.
Evolving Paradigms and shifting priorities in the landscape of Phase 1 Oncology Trials: 2021–2024 at the Targets25 NCI EORTC AACR Meeting:
• Targeted therapy trials dipped in 2023 but rebounded in 2024- KRAS inhibitors surged to 20% of the class.
• ADCs climbed from 4% to 20% of trials over 4 years, with TOP1 payloads dominating recent designs.
• Immunotherapy held steady, but bispecifics and CD3 engagers are gaining traction in early-phase pipelines.”
More posts featuring Vivek Subbiah on OncoDaily.